What is Inivata?
Founded in 2014 and headquartered in Morrisville, North Carolina, Inivata operates at the intersection of biotechnology and oncology. The company specializes in the development of advanced genomic tests that harness the potential of circulating tumor DNA (ctDNA). By providing clinicians with highly sensitive, non-invasive tools, Inivata facilitates earlier detection and more personalized treatment strategies for cancer patients. Its market position is defined by a rigorous focus on clinical validation and the integration of its technology into standard oncology workflows, effectively transforming how cancer is managed in a clinical setting.
How much funding has Inivata raised?
Inivata has raised a total of $136.5M across 4 funding rounds:
Angel/Seed
$6.5M
Series A
$45M
Corporate Investment
$25M
Series B
$60M
Angel/Seed (2014): $6.5M with participation from Johnson & Johnson Development Corporation, Imperial Innovations, and Cambridge Innovation Capital
Series A (2016): $45M led by Woodford Investment Management, Imperial Innovations, Cambridge Innovation Capital, and Johnson & Johnson Development Corporation
Corporate Investment (2020): $25M supported by NeoGenomics , Inc.
Series B (2021): $60M featuring Woodford Investment Management, Farallon Capital, JJDC, Janus Henderson Investors, Soleus Capital, Cambridge Innovation Capital, IP Group, and RT Ventures
Key Investors in Inivata
Cambridge Innovation Capital
Cambridge Innovation Capital is a venture capital investor focused on intellectual property-rich technology and life science businesses within the Cambridge ecosystem, dedicated to scaling brilliant technologies.
Woodford Investment Management
Woodford Investment Management is a financial services firm that historically managed various investment funds, providing capital solutions to high-growth potential enterprises.
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation is the strategic venture arm of the global healthcare giant, focusing on investments in pharmaceuticals and medical technologies that address critical unmet medical needs.
What's next for Inivata?
Looking ahead, Inivata is positioned to leverage its recent capital injection to broaden the clinical utility of its genomic testing suite. The strategic focus will likely center on expanding the adoption of its liquid biopsy solutions across international markets and deepening its partnerships with pharmaceutical entities for companion diagnostic development. As the oncology landscape shifts toward more personalized, data-driven interventions, Inivata's ability to provide real-time insights into tumor evolution will be paramount. The company remains focused on scaling its operational infrastructure to meet the growing demand for high-precision diagnostic tools, ensuring that its technological advancements translate into improved patient outcomes and long-term commercial viability.
See full Inivata company page
